Table 5 Cox proportional hazard regression analysis of risk factors for death-censored graft survival and patient survival
Death-censored graft survival | Patient survival | |||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
Donor | ||||||||
Male | 28.035 (0.023–34,659.316) | 0.359 | 1.426 (0.319–6.371) | 0.642 | ||||
Age | 0.996 (0.964–1.029) | 0.813 | 1.016 (0.965–1.069) | 0.545 | 0.992 (0.966–1.018) | 0.542 | 0.982 (0.942–1.023) | 0.382 |
Weight | 0.988 (0.960–1.017) | 0.407 | 0.973 (0.927–1.023) | 0.283 | 1.002 (0.975–1.028) | 0.909 | 1.009 (0.973–1.047) | 0.619 |
BMI | 0.915 (0.793–1.055) | 0.222 | 1.031 (0.918–1.159) | 0.603 | ||||
History of hypertension | 1.117 (0.232–5.376) | 0.891 | 1.076 (0.300–3.858) | 0.910 | ||||
History of diabetes | 0.046 (0–60,197.894) | 0.669 | 3.638 (0.814–16.255) | 0.091 | ||||
SCr At admission | 1.005 (0.982–1.030) | 0.665 | 1.023 (1.008–1.038) | 0.003 | ||||
SCr At terminal | 0.996 (0.984–1.008) | 0.492 | 1.004 (1.000–1.007) | 0.036 | ||||
AKI | 0.540 (0.112–2.599) | 0.442 | 0.344 (0.064–1.846) | 0.213 | 1.048 (0.351–3.127) | 0.933 | 0.603 (0.183–1.988) | 0.406 |
Stage 1 | 0.773 (0.097–6.177) | 0.808 | 1.034 (0.231–4.621) | 0.965 | ||||
Stage 2 | 0.889 (0.111–7.108) | 0.912 | 1.178 (0.264–5.263) | 0.830 | ||||
Stage 3 | 0.044 (0.000–1443.619) | 0.555 | 0.842 (0.110–6.434) | 0.868 | ||||
Recipients | ||||||||
Age | 0.833 (0.208–3.329) | 0.796 | 1.045 (0.980–1.115) | 0.178 | 1.031 (0.981–1.083) | 0.228 | 1.041 (0.987–1.099) | 0.137 |
Male | 1.021 (0.962–1.085) | 0.492 | 34.623 (0.267–4492.826) | 0.153 | ||||
BMI | 1.008 (0.914–1.113) | 0.867 | 1.000 (0.871–1.149) | 0.996 | 1.010 (0.943–1.083) | 0.768 | 0.991 (0.871–1.126) | 0.885 |
History of diabetes | 2.040 (0.255–16.309) | 0.502 | 1.225 (0.160–9.364) | 0.845 | ||||
History of hypertension | 1.297 (0.162–10.366) | 0.807 | 0.968 (0.217–4.325) | 0.966 | ||||
Days on dialysis | 0.952 (0.677–1.339) | 0.778 | 0.938 (0.672–1.309) | 0.705 | 0.953 (0.724–1.253) | 0.730 | 0.933 (0.711–1.223) | 0.615 |
Transplant | ||||||||
WIT | 1.007 (0.913–1.11) | 0.892 | 0.982 (0.886–1.088) | 0.724 | 1.037 (1.008–1.067) | 0.011 | 1.017 (0.984–1.050) | 0.318 |
CIT | 0.901 (0.713–1.139) | 0.382 | 0.861 (0.677–1.095) | 0.223 | 0.998 (0.843–1.181) | 0.981 | 0.968 (0.821–1.141) | 0.698 |
PRAI | 4.549 (0.945–21.898) | 0.059 | 0.045 (0–887.290) | 0.540 | ||||
PRAII | 0.047 (0–355,677.13) | 0.705 | 0.047 (0–17,233.146) | 0.640 | ||||
HLA mismatches | 1.256 (0.642–2.456) | 0.505 | 1.367 (0.664–2.813) | 0.396 | 0.914 (0.544–1.534) | 0.733 | 1.007 (0.583–1.742) | 0.979 |
DGF | 3.976 (1.068–14.806) | 0.040 | 7.096 (1.598–31.505) | 0.010 | 5.680 (1.903–16.948) | 0.002 | 6.189 (1.905–20.106) | 0.002 |
AR | 8.548 (2.295–31.845) | 0.001 | 9.039 (2.339–34.933) | 0.001 | 2.653 (0.832–8.460) | 0.099 | 2.195 (0.621–7.759) | 0.223 |
Induction immunosuppression (n, %) | ||||||||
Basiliximab | 0.250 (0.031–1.998) | 0.191 | 0.555 (0.155–1.991) | 0.367 | ||||
ATG | 1.129 (0.303–4.207) | 0.856 | 1.598 (0.535–4.769) | 0.401 | ||||
No-use | 3.039 (0.760–12.153) | 0.116 | 1.016 (0.227–4.538) | 0.984 | ||||